ArticleMolecular medicine (Cambridge, Mass.)2025
Epimedium brevicornum Maxim alleviates diabetes osteoporosis by regulating AGE-RAGE signaling pathway.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Natural Polysaccharide-Mediated Nano-Delivery Systems for Osteoporosis Therapy From a Gut-Bone Axis Regulatory Perspective.Advanced healthcare materials · 2026Review
- Evolutionary Characteristics and Expression Patterns of theCurrent issues in molecular biology · 2026Article
- Identification and validation of NETs-associated biomarkers in osteoporosis with diabetes.Scientific reports · 2026Article
- In Silico Investigation RevealsMedical sciences (Basel, Switzerland) · 2026Article
- Molecular mechanisms and preclinical evidence of natural products in diabetic osteoporosis: a review.Frontiers in endocrinology · 2026Review
- COL1A1 and SERPINE1 as Potential Therapeutic Targets in Diabetic Retinopathy: A Study Incorporating RNA Transcriptomics, Single-Cell RNA Sequencing, and Proteomics.Human mutation · 2026Article
- Molecular Mechanisms of Phthalates in Depression: An Analysis Based on Network Toxicology and Molecular Docking.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesEpimedium brevicornum Maxim (EP) has a history of utilization in Chinese traditional medicine for the treatment of bone diseases. However, the precise mechanism by which EP extract (EPE) operates in Diabetes osteoporosis (DOP) remains ambiguous. The study was aimed to explore the effects and underlying mechanisms of EPE on DOP, with particular emphasis on the AGE-RAGE pathway.
methodsThe DOP model was induced through a combination of a high-sugar and high-fat diet along with streptozotocin injection. Following treatment with EPE, blood glucose levels, body weight, and serum biomarkers were measured. The trabecular microstructure of the femur was analyzed using micro-CT tomography and H&E staining. Bioinformatics techniques, including network pharmacology and molecular docking, were utilized to identify key targets of EP for DOP. The predicted targets and pathways were further validated through RT-PCR, TSA analysis ELISA, and western blotting (WB), respectively.
resultsThe findings from animal experiments indicate that EPE has a positive impact on weight and blood glucose levels, particularly in reversing the decrease and disordered arrangement of bone trabeculae. Bioinformatics analysis reveals the involvement of the AGE-RAGE pathways in the treatment of DOP with EPE. Subsequent animal validation experiments demonstrate that EPE can regulate key proteins AGE-RAGE pathway, resulting in reducing the inflammatory factors and apoptosis, including advanced Glycation End-products (RGEs), receptor for Advanced Glycation End-products (RAGE), Interleukin-6 (IL-6), Interleukin-1β (IL-1β), Nuclear Factor Kappa B (NF-κB), BCL2-Associated X protein (Bax), B-cell lymphoma 2(Bcl2), and etc.
conclusionThis study provides clear evidence that EPE mitigates DOP through enhancement of the AGE-RAGE pathways, offering innovative insights and approaches for clinical utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.